内容紹介
The Effect of Immunotherapy and Hyperthermia on Advanced or Recurrent Ovarian and Uterine Cancer―229 Clinical Cases
Summary
We treated 116 advanced or recurrent ovarian cancer and 102 uterine cancer patients with hyperthermia and/or immunotherapy(2005/7-2013/11). Of these, 63, 31, and 8 patients had cervical cancer, endometrial cancer, and uterine sarcoma, respectively. Standard therapy showed no effect or was refused by these patients. Twenty-nine(25.0%)ovarian cancer patients experienced a clinical benefit(complete response[CR], partial response[PR], and long-term stable disease[SD], >6 months). The effective rate of a combination of therapies including activated lymphocyte therapy, dendritic cell therapy, and hyperthermia was 47.5%. Thirteen(12.7%)uterine cancer patients experienced a clinical benefit. The effective rates for cervical cancer, endometrial cancer, and uterine sarcoma were 7.9%, 22.5%, and 12.5%, respectively. Both hyperthermia and immunotherapy were administered to successfully treat these patients.
要旨
2005年7月～2013年11月に当院において,評価可能な116例の進行再発卵巣癌患者と102例の進行再発子宮悪性腫瘍患者に免疫療法・温熱療法を施行した。子宮頸癌63例,子宮体癌31例,子宮肉腫が8例であった。治療開始後6か月で判定したclinical benefit case(CR+PR+long SD)を有効と判定し,卵巣癌の有効例は29例(25.0%)と高く,特に活性化リンパ球,樹状細胞,温熱療法の三者併用での有効率が47.5%と最も高く,実質臓器への多発転移に有効であった。子宮悪性腫瘍への有効例は13例(12.7%),そのうち子宮頸癌は5例(7.9%),子宮体癌は7例(22.5%),子宮肉腫は1例(12.5%)であった。卵巣癌,子宮悪性腫瘍ともに温熱療法・免疫療法単独ではほとんど有効例は認められなかったが,併用にて有効が認められた。
目次
Summary
We treated 116 advanced or recurrent ovarian cancer and 102 uterine cancer patients with hyperthermia and/or immunotherapy(2005/7-2013/11). Of these, 63, 31, and 8 patients had cervical cancer, endometrial cancer, and uterine sarcoma, respectively. Standard therapy showed no effect or was refused by these patients. Twenty-nine(25.0%)ovarian cancer patients experienced a clinical benefit(complete response[CR], partial response[PR], and long-term stable disease[SD], >6 months). The effective rate of a combination of therapies including activated lymphocyte therapy, dendritic cell therapy, and hyperthermia was 47.5%. Thirteen(12.7%)uterine cancer patients experienced a clinical benefit. The effective rates for cervical cancer, endometrial cancer, and uterine sarcoma were 7.9%, 22.5%, and 12.5%, respectively. Both hyperthermia and immunotherapy were administered to successfully treat these patients.
要旨
2005年7月～2013年11月に当院において,評価可能な116例の進行再発卵巣癌患者と102例の進行再発子宮悪性腫瘍患者に免疫療法・温熱療法を施行した。子宮頸癌63例,子宮体癌31例,子宮肉腫が8例であった。治療開始後6か月で判定したclinical benefit case(CR+PR+long SD)を有効と判定し,卵巣癌の有効例は29例(25.0%)と高く,特に活性化リンパ球,樹状細胞,温熱療法の三者併用での有効率が47.5%と最も高く,実質臓器への多発転移に有効であった。子宮悪性腫瘍への有効例は13例(12.7%),そのうち子宮頸癌は5例(7.9%),子宮体癌は7例(22.5%),子宮肉腫は1例(12.5%)であった。卵巣癌,子宮悪性腫瘍ともに温熱療法・免疫療法単独ではほとんど有効例は認められなかったが,併用にて有効が認められた。